Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL

Chronic Lymphocytic Lymphoma Clinical Trial

Official title:
A Phase I/II Study of Immunotherapy With Milatuzumab (hLL1) in Patients With Chronic Lymphocytic Leukemia (CLL)

Status Completed

Clinical Trial Summary

This study will test different doses of anti-CD74 antibody in patients with NHL and/or CLL.

Clinical Trial Description

Milatuzumab (hLL1, IMMU-115), a humanized anti-CD74 monoclonal antibody. Dose escalation will utilize 4 planned dose regimens with 4.0 or 8.0 mg/kg doses administered intravenously either twice weekly (days 1 and 4) or thrice weekly (days 1, 3 and 5) for 4 consecutive weeks. The four planned dose regimens will be labeled as dose level 1 to 4 corresponding to increasing levels of the total dose of milatuzumab. ;

Study Design

Related Conditions & MeSH terms

Chronic Lymphocytic Lymphoma
Leukemia, Lymphocytic, Chronic, B-Cell

Clinical Trial Details

NCT number	NCT00603668
Study type	Interventional
Source	Gilead Sciences
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	August 2008
Completion date	February 2013

View Details

See also
	Status	Clinical Trial	Phase
	Active, not recruiting	`NCT04599634` - Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies	Phase 1
	Recruiting	`NCT00935597` - Host Dendritic Cells in Allograft Patients	Phase 1